Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q2 2024 Earnings Call Transcript
Operator: Good afternoon. And welcome to the Tarsus’ Second Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Tarsus Pharmaceuticals Inc. (TARS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Tang Capital Management Kevin C. Tang | 2,254,797 | $61,285,382 | 6.24% | |
| 2. | Perceptive Advisors Joseph Edelman | 1,296,416 | $35,236,587 | 0.84% | |
| 3. | Ikarian Capital Neil Shahrestani | 800,277 | $21,751,529 | +13% | 3.78% |
| 4. | Integral Health Asset Management Bhagwan Jay Rao | 590,000 | $16,036,200 | 1.52% | |
| 5. | Vivo Capital Albert Cha And Frank Kung | 565,550 | $15,371,649 | 1.41% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.96 | 1,000 | Director | 3,000 | 2023-12-15 | Filing | |
| $16.80 | 9,506 | Director | 15,866 | 2023-08-15 | Filing | |
| $16.29 | 6,360 | Director | 6,360 | 2022-09-14 | Filing | |
| $16.03 | 12,040 | Director | 12,040 | 2022-09-14 | Filing | |
| $13.50 | 100,000 | Director | 100,000 | 2022-05-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $26.53 | 5,021 | 0 | 2024-08-12 | Filing | ||
| $26.01 | 29,979 | 5,021 | 2024-08-12 | Filing | ||
| $27.47 | 10,445 | Officer | 18,136 | 2024-06-18 | Filing | |
| $30.60 | 4,766 | Officer | 54,075 | 2024-03-18 | Filing | |
| $30.60 | 4,436 | Officer | 40,951 | 2024-03-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,152,341 | $63,834,905 | 0.99% | |
| 2. | 2,516,139 | $50,951,816 | 0% | |
| 3. | 1,957,688 | $39,643,184 | 0% | |
| 4. | 1,911,399 | $38,705,829 | 2.53% | |
| 5. | 1,787,527 | $36,197,422 | 1.93% |
News See All
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript
Operator: Good afternoon, and welcome to Tarsus's First Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Aggressive Stock Portfolio: 13 Stocks Picked by Analysts
In this article, we will take a look at aggressive stock portfolio: 13 stocks picked by analysts.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.31, expectations were $-1.37. Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2023 Earnings Call Transcript
Operator: Good afternoon and welcome to the Tarsus Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. As a reminder, this call is being recorded.
15 Most Shorted Stocks That Are Loved By Analysts
In this piece, we will take a look at the 15 most shorted stocks that are loved by analysts.
Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Cathie Wood, Dan Sundheim, Tiger Global Management, Aurelius Capital Management, Tarsus Pharmaceuticals Inc (TARS), Appian Corporation (APPN), and More
Hedge fund manager Bill Ackman and Peter Thiel, an ally of former President Donald Trump, are backing a startup investing firm that says it plans to go head to head against large money managers that promote...
Billionaire Hedge Funds
